Survival of patients with salivary gland malignancies depending on the molecular profile of the tumor
- 16 November 2020
- journal article
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
Abstract
Introduction. Standard methods of drug or radiation therapy administration for salivary gland cancer is the least successful for now. Therefore, the identification of new markers with morphological features is extremely necessary to improve the effectiveness of treatment and increase the survival rates of patients with this pathology.The study objective is to assess the prevalence of expression of HER2/neu, PD-L1, and RET mRNA in salivary gland malignancies and assess their impact on overall and disease-free survival.Materials and methods. Fifty-nine patients with a confirmed diagnosis of salivary gland cancer (stages II–IVA) were examined in the period from 2012 to 2014 at Saint Petersburg City Clinical Oncology Dispensary. All materials were subjected to immunohistochemical research to determine the expression of HER2, PD-L1 in tumor and immune cells, the CPS index was calculated, and the frequency of the mRNA gene RET expression using a real-time polymerase chain reaction was detected.Results. The overall survival of patients with mild and high HER2 expression was 41 months (95 % confidence interval (CI) 4.50–72.00), which is more than 4 time less than in patients with low or no expression (p = 0.00715). Significant differences were also received in the progression-free survival in the group of patients with negative or insignificant expression of HER2 receptors. The overall survival of patients with CPS >1 was 72 months (95 % CI 19.5–72.00) and significantly differed from the group of patients with CPS Conclusion. When analyzing the obtained data, it was proved that knowledge of the salivary glands malignant tumors receptor status become one of the factors in determining the prognosis of the disease, as well as a predictive factor of targeted drugs effectiveness (after сonducting prospective randomized studies).This publication has 16 references indexed in Scilit:
- Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating LymphocytesCancer Immunology Research, 2016
- Programmed death ligand‐1 expression is associated with poor disease free survival in salivary gland carcinomasJournal of Surgical Oncology, 2016
- Classification of Salivary Gland NeoplasmsAdvances in oto-rhino-laryngology, 2016
- Human Epidermal Growth Factor Receptor 2 ( HER2/neu ) in Salivary Gland Carcinomas: A Review of LiteratureJournal of Clinical and Diagnostic Research, 2015
- Rare cancers of the head and neck area in EuropeEuropean Journal of Cancer, 2011
- Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic reviewThe Lancet Oncology, 2011
- Mammary Analogue Secretory Carcinoma of Salivary Glands, Containing the ETV6-NTRK3 Fusion Gene: A Hitherto Undescribed Salivary Gland Tumor EntityThe American Journal of Surgical Pathology, 2010
- American Society of Radiation Oncology Recommendations for Documenting Intensity-Modulated Radiation Therapy TreatmentsEndocrine, 2009
- An Update on Grading of Salivary Gland CarcinomasHead and Neck Pathology, 2009
- Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Locoregionally Advanced Laryngeal and Hypopharyngeal CancersEndocrine, 2007